Immupharma PLC Completion of LupuzorT Pivotal Phase III Study (2020C)
January 18 2018 - 2:00AM
UK Regulatory
TIDMIMM
RNS Number : 2020C
Immupharma PLC
18 January 2018
18 JANUARY 2018
ImmuPharma PLC
("ImmuPharma" or the "Company")
Completion of Lupuzor(TM) Pivotal Phase III Study and Initiation
of Follow Up Study
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and
development company, is pleased to confirm that the ongoing
52-week, randomised, double-blinded, Phase III clinical trial of
Lupuzor(TM), its lead programme for the potential breakthrough
compound for Lupus, is now complete, following the last patient
having attended their final assessment.
Final patient data from the trial are being collated and entered
into the database, checked and analysed. This process is ongoing
and top line results remain on track to be reported by the end of
Q1 2018.
At completion, we continue to observe a robust safety profile
over the 12 month period of patients' participation in the
trial.
Separately, following requests from both Investigators and
patients involved in the Phase III study, ImmuPharma is initiating
a "follow-up" study permitting eligible patients from the completed
Phase III study, to receive Lupuzor(TM) (plus "Standard of Care")
for a further six months in an open-label scheme. The results will
be gathered as an "extension" open label study, independent of the
pivotal Phase III trial which is now completed.
Commenting on the trial update, Robert Zimmer (MD, PhD),
President & CSO said: "We are delighted to announce this major
milestone for ImmuPharma in having completed on track this pivotal
Phase III trial for Lupuzor(TM).
"I would like to take this opportunity of thanking all of our
Clinical Investigators; Simbec-Orion, our clinical research
organisation and the ImmuPharma France team led by Dr Fanny
Valleix, Head of Clinical Research. All were paramount in the
execution and completion of this trial.
"With the continued robust safety achieved over this trial, we
look forward with continued confidence to reporting top line
results of the study this Q1 2018."
For more information on the trial please visit:
https://clinicaltrials.gov/ct2/show/NCT02504645
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
For further information please
contact:
+ 44 (0) 20
ImmuPharma plc (www.immupharma.com) 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor
Relations + 44 (0) 7721
Twitter: @immupharma 413496
Northland Capital Partners Limited
David Hignell, Jamie Spotswood,
Corporate Finance +44 (0)20 3861
Rob Rees, Corporate Broking 6625
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESBRMJTMBJBTBP
(END) Dow Jones Newswires
January 18, 2018 02:00 ET (07:00 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Sep 2023 to Sep 2024